Barclays Initiates Coverage of MiniMed Group with Equal-Weight
Fintel reports that on October 7, 2026, Barclays initiated coverage of MiniMed Group (NASDAQGS:MMED) (DB:B8S) with a Equal-Weight recommendation.
This action follows a prior initiation by Barclays on April 1, 2026, when the firm initiated coverage with an Overweight rating. Additionally, on September 24, 2026, Truist Securities initiated coverage on MiniMed Group with a Buy rating.
Prior to the rating action, on October 6, 2026, MiniMed Group's stock closed at $19.64. This pre-action close of $19.64 is also the latest close recorded on October 6, 2026. The stock has experienced a price change of -2.00% over one week, relative to a baseline close of $20.04 on September 29, 2026. Over a one-month period, the stock has seen a price change of -15.65% from a baseline close of $23.28 on September 4, 2026.
MiniMed Group last reported earnings on September 1, 2026. The company reported an actual earnings per share (EPS) of 0, compared to an estimate of 0.0952, representing an EPS surprise percent of -100.00%. Actual revenue for the period was $843,000,000.00, which was below the estimated revenue of $843,606,708.00.
Separately from Barclays' individual rating, the broader consensus target data as of October 2, 2026, shows a current consensus target mean of $26.52 and a median of $27.03. This mean target represents an implied change percent of +35.03% from the stock's recent levels. The prior consensus target mean was $26.24 as of September 15, 2026, reflecting a consensus target revision percent of +1.06%.
In terms of aggregate recommendations, the current recommendation period as of September 1, 2026, shows a total of 18 recommendations, consisting of 6 strong buy, 10 buy, 2 hold, 0 sell, and 0 strong sell ratings. This results in a positive percent of 88.9%, a hold percent of 11.1%, and a negative percent of 0.0%. These figures are unchanged from the prior recommendation period as of August 1, 2026, which also recorded a total of 18 recommendations with 6 strong buy, 10 buy, 2 hold, 0 sell, and 0 strong sell ratings, representing a positive percent of 88.9%, a hold percent of 11.1%, and a negative percent of 0.0%.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| October 7, 2026 | Barclays | Equal-Weight | initiated coverage | |
| September 24, 2026 | Truist Securities | Buy | initiated coverage |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.